As far as hot beauty trends go, eyelash lengthening is becoming the new teeth whitening—but with its newfound popularity has come loads of controversy. Last fall, the FDA pulled Jan Marini’s Age Intervention Eyelash from shelves after alleging that the product, which includes an ingredient similar to one in the glaucoma drug Lumigan, could lead to decreased vision. Shortly thereafter, Allergan, the company that makes Lumigan (and Botox) and is in the process of creating its own lash strengthening product, filed a patent infringement against both Marini and Athena Cosmetics, which makes another product, Revitalash. In March, Peter Thomas Roth is launching his Lashes to Die For, which he promises will be opthamologist-tested and approved (he’s staying mum on the active ingredients for now). But considering the health concerns surrounding lash growth formulas, the product seems ill-named, no? “It’s just a fun, playful name,” Roth laughed, noting that he came up with it before the controversy began.
